Company / Working Capital
Lineage Cell Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$47.8M
FY2025
5-year range
$20.5M / $64.4M
FY2021-FY2025
Trend
+29.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 10 years, ranging from $17M in FY2016 to $64M in FY2021.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of +5.7%.
Improved from $20M to $48M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +5.2%
- 5-Year CAGR
- +5.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +5.7%, indicating consistent growth.
- In FY2025, working capital increased 29.1% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.8M | +29.1% |
| FY2024 | $37.0M | +80.8% |
| FY2023 | $20.5M | -50.1% |
| FY2022 | $41.0M | -36.3% |
| FY2021 | $64.4M | +77.8% |
| FY2020 | $36.2M | -29.0% |
| FY2019 | $51.0M | +72.7% |
| FY2018 | $29.5M | -17.3% |
| FY2017 | $35.7M | +112.8% |
| FY2016 | $16.8M | -51.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026